Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

26.25
+0.14000.54%
Pre-market: 26.08-0.1700-0.65%08:58 EST
Volume:202.87K
Turnover:5.26M
Market Cap:934.89M
PE:-27.93
High:26.30
Open:25.90
Low:25.19
Close:26.11
Loading ...

Harrow announces Amir Shojaei, PharmD, PhD joins as CSO

TIPRANKS
·
07 Jan

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

THOMSON REUTERS
·
07 Jan

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Business Wire
·
07 Jan

3 US Growth Stocks With Insider Ownership Expecting Up To 85% Earnings Growth

Simply Wall St.
·
24 Dec 2024

B. Riley Lowers Price Target on Harrow to $69 From $73, Maintains Buy Rating

MT Newswires Live
·
04 Dec 2024

US Growth Stocks With High Insider Ownership To Watch

Simply Wall St.
·
25 Nov 2024

Harrow Says ImprimisRx Unit Wins Jury Verdict in Trademark Infringement Case

MT Newswires Live
·
21 Nov 2024

Harrow’s Imprimisrx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in Imprimisrx, Llc V. Osrx, Inc.

THOMSON REUTERS
·
21 Nov 2024

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Business Wire
·
21 Nov 2024

Stock Track | Harrow Health Soars Over 5% as Former Subsidiary Melt Pharmaceuticals Reports Positive Trial for Non-Opioid Sedative Drug

Stock Track
·
20 Nov 2024

Stock Track | Harrow Health Inc Soars 5.04% Pre-Market on Positive Trial Results for Spinoff Melt Pharmaceuticals' Sedative Drug

Stock Track
·
20 Nov 2024

ADVISORY-Alerts on Melt Pharmaceuticals wrongly tagged to Harrow Inc withdrawn

Reuters
·
20 Nov 2024

Harrow Inc - Melt-300 Shows Favorable Safety Profile Comparable to Placebo

THOMSON REUTERS
·
20 Nov 2024

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

THOMSON REUTERS
·
20 Nov 2024

Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery

Business Wire
·
20 Nov 2024

Stock Track | Harrow Health Inc (HROW) Plummets 5.09% as Q3 Earnings Reveal Operational Challenges Despite Record Revenue

Stock Track
·
15 Nov 2024